Angiotensin-converting enzyme inhibition reduces lipid deposits in myocardium and improves left ventricular function of obese zucker rats

Obesity

Volumn 14, Issue 9, 2006, Pages 1586-1595

  Toblli, Jorge Eduardo ^a   Cao, Gabriel ^a   Rivas, Carlos ^a   DeRosa, Graciela ^a   Domecq, Patricia ^a  

^a HOSPITAL ALEMÁN   (Argentina)

Author keywords

Amlodipine; Angiotensin converting enzyme inhibitor; Cardiac steatosis; Zucker rats

Indexed keywords

AMLODIPINE; CHOLESTEROL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; INSULIN; RAMIPRIL; TRIACYLGLYCEROL;

ANIMAL; ARTICLE; BLOOD; BLOOD PRESSURE; DRUG EFFECT; GLUCOSE BLOOD LEVEL; HEART LEFT VENTRICLE FUNCTION; HUMAN; LIPID METABOLISM; MALE; METABOLISM; PHYSIOLOGY; RANDOMIZATION; RAT; ZUCKER RAT;

AMLODIPINE; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; BLOOD GLUCOSE; BLOOD PRESSURE; CHOLESTEROL; HUMANS; INSULIN; LIPID METABOLISM; MALE; RAMIPRIL; RANDOM ALLOCATION; RATS; RATS, ZUCKER; TRIGLYCERIDES; VENTRICULAR FUNCTION, LEFT;

RATTUS;

EID: 33846804285     PISSN: 19307381     EISSN: 1930739X     Source Type: Journal    
DOI: 10.1038/oby.2006.183     Document Type: Article

References (61)

1. Levy D, Larson MG, Vasan RS, Kannel WB, Ho KK. The progression from hypertension to congestive heart failure. JAMA. 1996;275:1557-62.
2. Schunkert H. Obesity and target organ damage: the heart. Int J Obes Relat Metab Disord. 2002;26(Suppl 4):S15-20.
3. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA. 2002;287: 356-9.
4. Ho SC, Chen YM, Woo JL, Leung SS, Lam TH, Janus ED. Association between simple anthropometric indices and cardiovascular risk factors. Int J Obes Relat Metab Disord. 2001;25:1689-97.
5. Kremer D, Lindop G, Brown WC, Morton JJ, Robertson JI. Angiotensin-induced myocardial necrosis and renal failure in the rabbit: distribution of lesions and severity in relation to plasma angiotensin II concentration and arterial pressure. Cardiovasc Res. 1981;15:43-6.
6. Gavras H, Brown JJ, Lever AF, Mac Adam RF, Robertson JIS. Acute renal failure, tubular necrosis and myocardial infarction induced in the rabbit by intravenous angiotensin II. Lancet. 1971;ii:19-22.
7. Gavras H, Kramer D, Brown JJ, et al. Angiotensin and norepinephrine-induced myocardial lesions: experimental and clinical studies in rabbits and man. Am Heart J. 1975;89: 321-32.
8. Giacomelli F, Anversa P, Wiener J. Effect of angiotensininduced hypertension on rat coronary arteries and myocardium. Am J Pathol. 1976;84:111-38.
9. Sharma AM, Janke J, Gorzelniak K, Engeli S, Luft FC. Angiotensin blockade prevents type 2 diabetes by formation of fat cells. Hypertension. 2002;40:609-11.
10. Engeli S, Schling P, Gorzelniak K, et al. The adipose-tissue renin-angiotensin-aldosterone system: role in the metabolic syndrome? Int J Biochem Cell Biol. 2003;35:807-25.
11. de Cavanagh EMV, Inserra F, Toblli JE, Stella I, Fraga C, Ferder L. Enalapril attenuates oxidative stress in diabetic rats. Hypertension. 2001;38:1130-6.
12. Unger T, Li J. The role of the renin-angiotensin-aldosterone system in heart failure. J Renin Angiotensin Aldosterone Syst. 2004;5(Suppl 1):S7-10.
13. Lassila M, Davis BJ, Allen TJ, Burrell LM, Cooper ME, Cao Z. Cardiovascular hypertrophy in diabetic spontaneously hypertensive rats: optimizing blockade of the renin-angiotensin system. Clin Sci (Land). 2003;104:341-7.
14. Grossman E, Messerli FH. Cardiac effects of calcium antagonist in hypertension. In: Calcium Antagonists in Clinical Medicine by Murray Epstein. 3rd ed. Philadelphia, PA: Hanley & Belfus, Inc.; pp. 207-28.
15. Manning WJ, Wei JY, Katz SE, Litwin SE, Douglas PS. In vivo assessment of LV mass in mice using high-frequency cardiac ultrasound: necropsy validation. Am J Physiol. 1994;266:H1672-5.
16. Gardin JM, Siri FM, Kitsis RN, Edwards JG, Leinwand LA. Echocardiographic assessment of left ventricular mass and systolic function in mice. Circ Res. 1995;76:907-14.
17. Hoit BD, Khoury SF, Kranias EG, Ball N, Walsh RA. In vivo echocardiographic detection of enhanced left ventricular function in gene-targeted mice with phospholamban deficiency. Circ Res. 1995;77:632-7.
18. Tanaka N, Dalton N, Mao L, et al. Transthoracic echocardiography in models of cardiac disease in the mouse. Circulation. 1996;94:1109-17.
19. + intakes. Am J Physiol Heart Circ Physiol. 1996;270: H628-37.
20. Roth DM, Swaney JS, Dalton ND, Gilpin EA, Ross J Jr. Impact of anesthesia on cardiac function during echocardiography in mice. Am J Physiol Heart Circ Physiol. 2002;282: H2134-40.
21. Zhou YT, Grayburn P, Karim A, et al. Lipotoxic heart disease in obese rats: implications for human obesity. Proc Natl Acad Sci USA. 2000;97:1784-9.
22. Bray GA. The Zucker-fatty rat: a review. Fed Proc. 1977;36: 148-53.
23. Kava R, Greenwood MR, Johnson PR. Zucker (fa/fa) rats. ILAR News. 1990:32:4-8
24. Kurtz TW, Morris RC, Pershadsingh HA. The Zucker fatty rat as a genetic model of obesity and hypertension. Hypertension. 1989;13:896-901.
25. van Zwietenn PA. Diabetes and hypertension: experimental models for pharmacological studies. Clin Exp Hypertens. 1999;21:1-6.
26. Linz W, Wohlfart P, Schoelkens BA, Becker RH, Malinski T, Wiemer G. Late treatment with ramipril increases survival in old spontaneously hypertensive rats. Hypertension. 1999;34:291-5.
27. Zimmermann R, Kastens J, Linz W, Wiemer G, Schoelkens BA, Schaper J. Effect of long-term ACE inhibition on myocardial tissue in hypertensive stroke-prone rats. J Mol Cell Cardiol. 1999;8:1447-56.
28. Toblli JE, Stella I, Mazza ON, Ferder L, Inserra F. Different effect of losartan and amlodipine on penile structures in male spontaneously hypertensive rats. Am J Nephrol. 2004;24:614-23.
29. Kim S, Zhan Y, Izumi Y, Iwao H. Cardiovascular effects of combination of perindopril, candesartan and amlodipine in hypertensive rats. Hypertension. 2000:35:769-74.
30. Litwin SE, Katz SE, Morgan JP, Douglas PS. Serial echocardiographic assessment of left ventricular geometry and function after large myocardial infarction in the rat. Circulation. 1994;89:345-54.
31. Devereux RB, Alonso DR, Lutas EM, et al. Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol. 1986:57:450-8.
32. Chung ES, Pelini S, Aurigemma GP, Fenton RA, Dobson JG, Meyer TE. Effects of chronic adenosine uptake blockade on adrenergic responsiveness and left ventricular chamber function in pressure overload hypertrophy in the rat. J Hypertens. 1998:16:1813-22.
33. Toblli JE, DeRosa G, Rivas C, et al. Cardiovascular protective role of a low-dose antihypertensive combination in obese Zucker rats. J Hypertens. 2003:21:611-20.
34. Janke J, Engeli S, Gorzelniak K, Luft FC, Sharma AM.Mature adipocytes inhibit in vitro differentiation of human preadipocytes via angiotensin-type 1 receptors. Diabetes. 2002;51:1699-707.
35. Gorzelniak K, Engeli S, Janke J, Luft FC, Sharma AM. Hormonal regulation of the human adipose-tissue reninangiotensin system: relationship to obesity and hypertension. J Hypertension. 2002;20:965-73.
36. Park BH, Lee Y, Walton M, Duplomb L, Unger RH. Demonstration of reverse fatty acid transport from rat cardiomyocytes. J Lipid Res. 2004;45:1992-9.
37. Shimabukuro M, Koyama K, Chen G, et al. Direct antidiabetic effect of leptin through triglyceride depletion of tissues. Proc Natl Acad Sci USA. 1997;94:4637-41.
38. Lee Y, Hirose H, Zhou YT, Esser V, McGarry JD, Unger RH. Increased lipogenic capacity of the islets of obese rats: a role in the pathogenesis of NIDDM. Diabetes. 1997:46:408-13.
39. Qian H, Azain MJ, Hartzell DL, Baue CA. Increased leptin resistance as rats grow to maturity. PSEBM. 1998;219:160-5.
40. Wang ZW, Pan WT, Lee Y, Kakuma T, Zhou YT, Unger RH. The role of leptin resistance in the lipid abnormalities of aging. FASEB J. 2001;15:108-14.
41. Correia MLG, Haynes WG. Obesity-related hypertension: is there a role for selective leptin resistance? Curr Hypertens Rep. 2004;6:230-5.
42. Fruhbeck G. Pivotal role of nitric oxide in the control of blood pressure after leptin administration. Diabetes. 1999:48: 903-8.
43. Unger RH, Orci L. Diseases of liporegulation: new perspective on obesity and related disorders. FASEB J. 2001:15:312-21.
44. Hunter JJ, Chien KR. Signaling pathways for cardiac hypertrophy and failure. N Engl J Med. 1999;341:1276-83.
45. Gealekman O, Abassi Z, Rubinstein I, Winaver J, Binah O. Role of myocardial inducible nitric oxide synthase in contractile dysfunction and beta-adrenergic hyporesponsiveness in rats with experimental volume-overload heart failure. Circulation. 2002;105:236-43.
46. Ren J, Sowers JR, Walsh MF, Brown RA. Reduced contractile response to insulin and IGF-I in ventricular myocytes from genetically obese Zucker rats. Am J Physiol Heart Circ Physiol. 2000;279:H1708-14.
47. Ren J, Walsh MF, Jefferson L, et al. Basal and ethanolinduced cardiac contractile response in lean and obese Zucker rat hearts. J Biomed Sci. 2000;7:390-400.
48. Wold LE, Relling DP, Duan J, Norby FL, Ren J. Abrogated leptin-induced cardiac contractile response in ventricular myocytes under spontaneous hypertension: role of Jak/STAT pathway. Hypertension. 2002;39:69-74.
49. 2[thorn] and NO. Am J Physiol. 1998;275:H823-30.
50. Vincent HK, Powers SK, Stewart DJ, Shanely RA, Demirel H, Naito H. Obesity is associated with increased myocardial oxidative stress. Int J Obes Relat Melab Disord. 1999:23:67-74.
51. Unger RH. How obesity causes diabetes in Zucker diabetic fatty rats. Trends Endocrinol Metab. 1998;7:276-82.
52. Shimabukuro M, Zhou YT, Levi M, Unger RH. Fatty acid-induced beta cell apoptosis: a link between obesity and diabetes. Proc Natl Acad Sci USA. 1998;95:2498-502.
53. Obeid LM, Linardic CM, Karolak LA, Hannun Y A. Programmed cell death induced by ceramide. Science. 1993;259: 1769-71.
54. Zhou MS, Jaimes EA, Raij L. Inhibition of oxidative stress and improvement of endothelial function by amlodipine in angiotensin II-infused rats. Am J Hypertens. 2004;17:167-71.
55. Ganafa A A, Walton M, Eatman D, Abukhalaf IK, Bayorh MA. Amlodipine attenuates oxidative stress-induced hypertension. Am J Hypertens. 2004;17:743-8.
56. Yasunari K, Maeda K, Watanabe T, Nakamura M, Yoshikawa J, Asada A. Comparative effects of valsartan versus amlodipine on left ventricular mass and reactive oxygen species formation by monocytes in hypertensive patients with left ventricular hypertrophy. J Am Coll Cardiol. 2004;43:2116-23.
57. Varin R, Mulder P, Tamion F, et al. Improvement of endothelial function by chronic angiotensin-converting enzyme inhibition in heart failure: role of nitric oxide, prostanoids, oxidant stress, and bradykinin. Circulation. 2000;102:351-6.
58. Inserra F, Romano L, Ercole L, de Cavanagh EM, Ferder L. Cardiovascular changes by long-term inhibition of the renin-angiotensin system in aging. Hypertension. 1995;25: 437-42.
59. de Cavanagh EM, Fraga CG, Ferder L, Inserra F. Enalapril and captopril enhance antioxidant defenses in mouse tissues. Am J Physiol. 1997;272:R514-8.
60. de Cavanagh EMV, Inserra F, Ferder L, Fraga CG. Enalapril and captopril enhance glutathione-dependent antioxidant defenses in mouse tissue. Am J Physiol. 2000;278: R572-7.
61. Toblli JE, Ferder L, Stella I, Angerosa M, Inserra F. Enalapril prevents fatty liver in nephrotic rats. J Nephrology. 2002;15:358-67.